Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7002174> ?p ?o }
Showing triples 1 to 51 of
51
with 100 triples per page.
- Q7002174 subject Q16780215.
- Q7002174 subject Q8301163.
- Q7002174 subject Q8401081.
- Q7002174 subject Q8403399.
- Q7002174 abstract "Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and located in San Diego, California. The company took its name from the original focus on therapies for neurological and endocrine diseases and disorders.The company endured a significant setback on May 16, 2006 when the Food and Drug Administration (FDA) denied approval for the 15-milligram dose of Indiplon, a medication to treat insomnia. Neurocrine had developed the drug and was seeking to market it with partner, Pfizer. Announcement of the setback led to a 62% drop in stock price. Subsequent disclosures related to attempts to overcome this major setback caused a further drop in the stock by 30% in November 2006.Lacking approval for Indiplon, the company laid off a 200-member sales force in July, 2006 and 100 employees across all areas of the company on August 7, 2006. It announced a further cut of half the remaining workforce in December 2007, and a fourth quarter loss of $128 million, including a $94 million write-off.But recently the company has recovered the long term hope for recovery. All started on the 25th of May, 2010 when the shares jumped nearly 25% after the company announced its drug to treat endometriosis had achieved its main and secondary goals in a study.The drug, called elagolix, reportedly showed statistically significant reductions in dysmenorrhea, or pelvic pain during menstruation as well as painful intercourse. And the shares of the company were up 69 cents to $3.40 on May the 25th trading, hitting a 52-week high of $4.23 early in the trading session.Since that, its stock price has climbed from $4.23 to $6.16 as of 25 June 2010.".
- Q7002174 foundingYear "1992".
- Q7002174 industry Q7108.
- Q7002174 location Q16552.
- Q7002174 location Q30.
- Q7002174 location Q99.
- Q7002174 numberOfEmployees "95".
- Q7002174 type Q891723.
- Q7002174 wikiPageExternalLink www.neurocrine.com.
- Q7002174 wikiPageWikiLink Q11078.
- Q7002174 wikiPageWikiLink Q12136.
- Q7002174 wikiPageWikiLink Q16552.
- Q7002174 wikiPageWikiLink Q16780215.
- Q7002174 wikiPageWikiLink Q204711.
- Q7002174 wikiPageWikiLink Q206921.
- Q7002174 wikiPageWikiLink Q30.
- Q7002174 wikiPageWikiLink Q6024927.
- Q7002174 wikiPageWikiLink Q7108.
- Q7002174 wikiPageWikiLink Q8301163.
- Q7002174 wikiPageWikiLink Q83042.
- Q7002174 wikiPageWikiLink Q8401081.
- Q7002174 wikiPageWikiLink Q8403399.
- Q7002174 wikiPageWikiLink Q891723.
- Q7002174 wikiPageWikiLink Q99.
- Q7002174 foundation "1992".
- Q7002174 homepage www.neurocrine.com.
- Q7002174 industry Q7108.
- Q7002174 keyPeople "Bill Rastetter, Chairman".
- Q7002174 keyPeople "Kevin C. Gorman, CEO/President".
- Q7002174 location Q16552.
- Q7002174 location Q30.
- Q7002174 location Q99.
- Q7002174 name "Neurocrine Biosciences".
- Q7002174 numEmployees "95".
- Q7002174 type "Public".
- Q7002174 type Organization.
- Q7002174 type Agent.
- Q7002174 type Company.
- Q7002174 type Organisation.
- Q7002174 type Agent.
- Q7002174 type SocialPerson.
- Q7002174 type Thing.
- Q7002174 type Q43229.
- Q7002174 comment "Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and located in San Diego, California. The company took its name from the original focus on therapies for neurological and endocrine diseases and disorders.The company endured a significant setback on May 16, 2006 when the Food and Drug Administration (FDA) denied approval for the 15-milligram dose of Indiplon, a medication to treat insomnia. Neurocrine had developed the drug and was seeking to market it with partner, Pfizer.".
- Q7002174 label "Neurocrine Biosciences".
- Q7002174 homepage www.neurocrine.com.
- Q7002174 name "Neurocrine Biosciences".